JP2017529354A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529354A5
JP2017529354A5 JP2017514869A JP2017514869A JP2017529354A5 JP 2017529354 A5 JP2017529354 A5 JP 2017529354A5 JP 2017514869 A JP2017514869 A JP 2017514869A JP 2017514869 A JP2017514869 A JP 2017514869A JP 2017529354 A5 JP2017529354 A5 JP 2017529354A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
glp
glucagon receptor
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017514869A
Other languages
English (en)
Japanese (ja)
Other versions
JP6832273B2 (ja
JP2017529354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2015/009753 external-priority patent/WO2016043533A1/en
Publication of JP2017529354A publication Critical patent/JP2017529354A/ja
Publication of JP2017529354A5 publication Critical patent/JP2017529354A5/ja
Application granted granted Critical
Publication of JP6832273B2 publication Critical patent/JP6832273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017514869A 2014-09-16 2015-09-16 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用 Active JP6832273B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140122862 2014-09-16
KR10-2014-0122862 2014-09-16
PCT/KR2015/009753 WO2016043533A1 (en) 2014-09-16 2015-09-16 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020159894A Division JP2021035942A (ja) 2014-09-16 2020-09-24 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用

Publications (3)

Publication Number Publication Date
JP2017529354A JP2017529354A (ja) 2017-10-05
JP2017529354A5 true JP2017529354A5 (enExample) 2018-10-25
JP6832273B2 JP6832273B2 (ja) 2021-02-24

Family

ID=55533503

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514869A Active JP6832273B2 (ja) 2014-09-16 2015-09-16 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用
JP2020159894A Withdrawn JP2021035942A (ja) 2014-09-16 2020-09-24 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020159894A Withdrawn JP2021035942A (ja) 2014-09-16 2020-09-24 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用

Country Status (26)

Country Link
US (2) US10233230B2 (enExample)
EP (1) EP3197483A4 (enExample)
JP (2) JP6832273B2 (enExample)
KR (3) KR102541971B1 (enExample)
CN (1) CN107106660B (enExample)
AR (1) AR101896A1 (enExample)
AU (3) AU2015318881A1 (enExample)
CA (1) CA2960657A1 (enExample)
CL (1) CL2017000638A1 (enExample)
CO (1) CO2017002689A2 (enExample)
CR (1) CR20170129A (enExample)
EA (1) EA201790568A1 (enExample)
EC (1) ECSP17022931A (enExample)
GT (1) GT201700056A (enExample)
IL (2) IL251060B (enExample)
MA (1) MA40466A (enExample)
MX (2) MX2017003438A (enExample)
MY (2) MY195618A (enExample)
NI (1) NI201700032A (enExample)
NZ (1) NZ730799A (enExample)
PE (1) PE20170778A1 (enExample)
PH (1) PH12017500486B1 (enExample)
SG (1) SG11201701841WA (enExample)
TW (2) TWI802396B (enExample)
WO (1) WO2016043533A1 (enExample)
ZA (2) ZA201701847B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
EP4523705A3 (en) 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
CN106046145B (zh) 2016-04-22 2022-11-04 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
EP3479841A4 (en) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
US11419918B2 (en) 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN111372945B (zh) * 2017-11-06 2024-02-02 中山大学 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化
EP4506017A3 (en) * 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
WO2019243502A1 (en) 2018-06-21 2019-12-26 Novo Nordisk A/S Novel compounds for treatment of obesity
WO2020128967A2 (en) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
DK3936142T3 (da) * 2019-06-28 2024-03-25 Hanmi Pharmaceutical Co Ltd Tredobbelt agonist med aktivitet med hensyn til alle glucagon-, GLP-1- og GLP-receptorer til behandling af leversygdom
US12558431B2 (en) 2019-07-18 2026-02-24 Hanmi Pharm. Co., Ltd. Method of preparing protein conjugate
KR20210103265A (ko) * 2020-02-13 2021-08-23 주식회사 제넥신 신규 비알코올성 지방간염 치료용 약학 조성물
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
NZ793813A (en) 2020-04-29 2025-12-19 Onegene Biotechnology Inc Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
CN113292646B (zh) 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
KR20220008788A (ko) * 2020-07-14 2022-01-21 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
EP4197550A4 (en) * 2020-08-14 2025-10-08 Hanmi Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
CN116963760A (zh) * 2020-12-22 2023-10-27 美迪引擎 用于预防或治疗酒精性和非酒精性脂肪肝病的药物组合物
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20240148879A1 (en) * 2021-02-21 2024-05-09 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
JP7642830B2 (ja) * 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116589536B (zh) * 2023-05-18 2024-01-23 江苏师范大学 一类长效glp-1/gip受体双重激动剂及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1999044630A1 (en) 1998-03-06 1999-09-10 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
ATE499088T1 (de) 2007-07-10 2011-03-15 Lilly Co Eli Glp-1-fc fusionsprotein-formulierung
CN103416421B (zh) 2007-07-27 2016-07-27 拜尔农作物科学股份公司 三元活性化合物结合物
WO2009033739A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CA2755336C (en) 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
MX2011009803A (es) 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
EP2443146B1 (en) * 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
EP2504021A4 (en) * 2009-11-23 2013-05-15 Amylin Pharmaceuticals Llc Polypeptide conjugate
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
RU2607365C2 (ru) 2011-06-17 2017-01-10 Ханми Сайенс Ко., Лтд. Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
KR20140043793A (ko) * 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途

Similar Documents

Publication Publication Date Title
JP2017529354A5 (enExample)
Li et al. Current drug research on PEGylation with small molecular agents
JP6389446B2 (ja) 免疫複合体製剤
Yang et al. Anti‐PEG immunity: emergence, characteristics, and unaddressed questions
IL274106B2 (en) The composition containing an oxyntomodulin derivative for the treatment of hyperlipidemia
JP6832273B2 (ja) 非アルコール性脂肪性肝疾患を治療するための長時間作用性ｇｌｐ−１／グルカゴン受容体デュアルアゴニストの使用
Wu et al. Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy
Eras et al. Chemical conjugation in drug delivery systems
JP2011505369A (ja) 薬剤の持続送達のための多糖ゲル組成物および方法
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
JP2015536942A5 (enExample)
JP2007529536A (ja) 抗体カリケアマイシン結合体
CN106456794A (zh) 接头药物与抗体的位点特异性缀合以及所得adc
JP2014129366A (ja) 免疫調節組成物及びその使用方法
AU2018361481A1 (en) Drug delivery systems and methods comprising polysialic acid and/or other polymers
US11529424B2 (en) Synthetic bioconjugates
JP2020510039A5 (enExample)
AU2016377775A1 (en) Immune cell-targeted particles
KR20180105261A (ko) Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물
CN101237881B (zh) 免疫偶联物剂型
CA2744670C (en) A b cell depleting agent for the treatment of atherosclerosis
Boland et al. Antitumor Activity of Death Receptor 5-Targeted Camptothecin-Loaded Nanoparticles in Murine Syngeneic Models
Abu Lila et al. Immune Response to PEGylated Nanomedicines: Impact of IgM Response
NZ724926A (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
NZ727871B2 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist